Bharat Biotech submits Phase III clinical trial data of 'Covaxin' to DCGI
- Bharat Biotech has submitted the data of the third phase trial of Corona's indigenous vaccine Covaxin to the country's top drug regulator DCGI.
- Government sources said that Bharat Biotech has submitted data for the Phase III clinical trial of Covaxin to the Drugs Controller General of India.
- The expert group is scheduled to meet today to consider the results of the data after Bharat Biotech released interim data from Phase III trials in March.
- It was said that it is up to 81 percent effective against the Covid-19 virus, although this data has not yet been published in any review journal.
- DCGI approved Covaxin for emergency use restricted to India in January based on its Phase 1 and 2 daily tests.
